Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Idiopathic Hypereosinophilic Syndrome With Cutaneous Manifestations: A Case Report.
Cureus
December 2024
Internal Medicine, Unidade Local De Saúde De São João, Porto, PRT.
Hypereosinophilic syndrome (HES) is marked by eosinophilic infiltration and the release of inflammatory mediators that cause damage to multiple organs. Despite careful evaluation of hypereosinophilia, the etiology of most cases remains undefined. Eosinophils may cause damage in almost all organs, and most patients present with dermatological manifestations.
View Article and Find Full Text PDFPulmonary Arterial Hypertension Associated With Idiopathic Hypereosinophilic Syndrome: Importance of Eosinophilia Control With Steroid Therapy.
CJC Open
January 2025
Department of Cardiovascular Medicine, Kyorin University, Tokyo, Japan.
Myocarditis with neurological and dermatological involvement in idiopathic Hypereosinophilic syndrome: Case report.
Radiol Case Rep
March 2025
Laboratory of Epidemiology, Clinical Research and Public Health, Faculty of Medicine and Pharmacy, Oujda, Morocco.
Eosinophilic myocarditis (EM), irrespective of its unique etiology, is marked by varying extents of eosinophil infiltration, frequently accompanied by peripheral eosinophilia. In some instances, the etiology remains undetermined, thus classified as idiopathic hypereosinophilic syndrome. The clinical manifestations are highly variable, ranging from mild or asymptomatic presentations to acute fulminant myocarditis or chronic restrictive cardiomyopathy.
View Article and Find Full Text PDFWells' Syndrome Associated With Idiopathic Hypereosinophilic Syndrome in a Child: A Case Report.
Cureus
December 2024
Dermatology and Venereology, Faculty of Medicine, Al-Azhar University, Cairo, EGY.
Wells' syndrome is a rare inflammatory disease characterized by recurrent, erythematous plaques with histological flame figures, which can be associated with idiopathic hypereosinophilic syndrome (IHES). We present a case of a nine-year-old boy who presented with a one-year history of an itchy rash on his legs associated with peripheral eosinophilia. The rash initially started as an annular plaque and developed raised borders with central hyperpigmentation.
View Article and Find Full Text PDFIntroduction: Benralizumab is an interleukin 5-receptor-blocking drug registered for the treatment of eosinophilic asthma. It has proven efficient and safe in a small phase-II trial in hypereosinophilic syndrome and is currently being investigated in a larger, randomized phase-III trial. We report on real-world experience with benralizumab in 15 patients with severe Hypereosinophilic syndrome (HES) that were refractory to other treatments or on unacceptable steroid doses.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!